These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22886820)

  • 41. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathology and function of conduction tissue in Fabry disease cardiomyopathy.
    Frustaci A; Morgante E; Russo MA; Scopelliti F; Grande C; Verardo R; Franciosa P; Chimenti C
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):799-805. PubMed ID: 26047621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.
    Schinkel AF
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):562-8. PubMed ID: 23673907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice.
    Vijapurapu R; Kozor R; Hughes DA; Woolfson P; Jovanovic A; Deegan P; Rusk R; Figtree GA; Tchan M; Whalley D; Kotecha D; Leyva F; Moon J; Geberhiwot T; Steeds RP
    Trials; 2019 May; 20(1):314. PubMed ID: 31151481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subcutaneous implantable cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy: Results from an Italian multicenter registry.
    Migliore F; Viani S; Bongiorni MG; Zorzi A; Silvetti MS; Francia P; D'Onofrio A; De Franceschi P; Sala S; Donzelli S; Ricciardi G; Menardi E; Giammaria M; La Greca C; Bauce B; Rigato I; Iliceto S; Bertaglia E; Diemberger I; Corrado D
    Int J Cardiol; 2019 Apr; 280():74-79. PubMed ID: 30661851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Transatlantic Experience.
    Orgeron GM; Bhonsale A; Migliore F; James CA; Tichnell C; Murray B; Bertaglia E; Cadrin-Tourigny J; De Franceschi P; Crosson J; Tandri H; Corrado D; Calkins H
    J Am Heart Assoc; 2018 Nov; 7(21):e008782. PubMed ID: 30608223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease.
    Krämer J; Niemann M; Störk S; Frantz S; Beer M; Ertl G; Wanner C; Weidemann F
    Am J Cardiol; 2014 Sep; 114(6):895-900. PubMed ID: 25073565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
    Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
    J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
    Rigopoulos AG; Daci S; Pfeiffer B; Papadopoulou K; Neugebauer A; Seggewiss H
    Clin Res Cardiol; 2016 Nov; 105(11):953-961. PubMed ID: 27270758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Patients with structural heart disease, syncope of unknown etiology and inducible ventricular arrhythmias treated with implantable defibrillators].
    Aguinaga L; Mont L; Anguera I; Valentino M; Matas M; Brugada J
    Rev Esp Cardiol; 1998 Jul; 51(7):566-71. PubMed ID: 9711105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
    Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
    Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L
    Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary and secondary prevention of ventricular arrhythmias in dilated cardiomyopathy: nonsustained, sustained, and incessant.
    Meyer C; Schueller P; Rodenbeck A; Hennersdorf M; Merx M; Winter J; Rassaf T; Kelm M; Schauerte P
    Int Heart J; 2009 Nov; 50(6):741-51. PubMed ID: 19952471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
    Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
    Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Arrhythmias in hypertrophic cardiomyopathy.
    Kuck KH
    Pacing Clin Electrophysiol; 1997 Oct; 20(10 Pt 2):2706-13. PubMed ID: 9358518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.
    Daimee UA; Vermilye K; Moss AJ; Goldenberg I; Klein HU; McNitt S; Zareba W; Kutyifa V
    Heart Rhythm; 2018 Sep; 15(9):1379-1386. PubMed ID: 29678779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of hypertrophic cardiomyopathy in children.
    Seggewiss H; Rigopoulos A
    Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society.
    Silka MJ; Kron J; Dunnigan A; Dick M
    Circulation; 1993 Mar; 87(3):800-7. PubMed ID: 8443901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.